TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean difference in number of patients achieving complete clinical clearance of lesion (PGA Score of 5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in number of days required to achieve complete clinical clearance of lesion (PGA Score of 5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of adverse effects (minor and serious)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in muscular balance's of upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in FIM
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Quick Dash
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Action Research Arm Test (ARAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Quebec User Evaluation of Satisfaction with Assistive Technology (QTEST)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in the Self-Assessment Manikin (SAM)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in actinic keratosis lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 28 day in-hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: acceptable dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Radiation Exposure to Patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation Exposure to Surgeon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation Exposure to Scrub Tech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with eosinophilic and non-eosinophilic phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in FLT uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Profile (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urological outcome following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Box and Blocks Test (BBT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction rate of hot flashes symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Connectivity Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Associative Memory Test Score Changes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vitamin A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Concentration of JNJ-64140284
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Concentration of JNJ-64140284
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AKI persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: monocular Best Corrected Distance Visual Acuity (CDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound size change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular incidence
Endpoint domain: Mortality/survival
Primary endpoint: Cerebrovascular incidence
Endpoint domain: Mortality/survival
Primary endpoint: Cerebrovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: New cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of the time taken in operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of the amount of contrast agent used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in assessment scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-Reported Ability to Participate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gas consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Achieving Clinical Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of markers of M1 and M2 macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection rates of clinically significant PCa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Number of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of capecitabine dose modifications due to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients That Experienced DLT
Endpoint domain: Adverse events/effects
Primary endpoint: KOOS (knee injury and osteoarthritis outcomes score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of people who sign up for the challenge
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of hepatocellular carcinoma (HCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression of Liver Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in total nasal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With 50% or Greater Pain Score Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal residual disease (MRD) negative second remission (Rem-2) rate
Endpoint domain: Mortality/survival
Primary endpoint: Event-free survival post-reinduction (EFS PR)
Endpoint domain: Mortality/survival
Primary endpoint: EFS PR
Endpoint domain: Mortality/survival
Primary endpoint: 6-month Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in physical activity behavior (teens)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical activity behavior (parents)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dietary behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of drug-related side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Adverse Events Leading to Dose Modification
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Death during follow up
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Hospitalization for Major Cardiovascular Events (MACEs) during follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of the Composite endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum human anti-murine antibodies (HAMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE)
Endpoint domain: Mortality/survival
Primary endpoint: Unexplained Death
Endpoint domain: Mortality/survival
Primary endpoint: Word Recognition in Quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Words-in-Noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of outpatient cervical ripening protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percutaneous tracheostomy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: serum concentration of CTRP-1, 3, or 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average time to change in antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of pain or paresthesia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of central line infections
Endpoint domain: Adverse events/effects
Primary endpoint: Procedure outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retention of sealant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change in clinical symptoms of spinal cord injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Gastrointestinal Symptom Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gait initiation kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCTA image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-τ) for darapladib and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for darapladib and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile (including maximum tolerated dose and dose limiting toxicities)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Lumbar Spine Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of change of maximal elastance of the right ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic accuracy of flexible-probe based CLE for urothelial carcinoma diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of surgical radicality after TURBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Assessment of depth of resection after TURBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to prostate specific antigen (PSA) recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Airway Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in fat balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Clinician's Erythema Assessment (CEA) or Patient Erythema Self-Assessment (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in respiratory frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in respiratory tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain Scores at needle insertion and at product injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Redness following product injection
Endpoint domain: Adverse events/effects
Primary endpoint: Pruritus following product injection
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of administration of 18F-αvβ6-BP
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Intolerance of Bystolic
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of children with sub-optimal growth by 2 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response or Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High Platelet Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SIS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Shear modulus measures in the external anal sphincter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in circulating number of endothelial progenitor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in brachial artery flow mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in anti-smoking self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anti-Erythropoietin (EPO) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adequacy of stopping or preventing bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial affect recognition performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Liberation from invasive ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of QL1205
Endpoint domain: Adverse events/effects
Primary endpoint: active range of motion (AROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Volume (FEV1) Peak (0-3h) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neurocognitive task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Variability in Microbiome Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in Stool Metabolome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in Plasma Metabolome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective lens position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological cost index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Heavy Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-Administered PTSD Scale (CAPS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: List Sorting Working Memory Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of urinary functional disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of Major Molecular Response (MMR) at 6 Cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMR Rate by 12 Cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Complete Cytogenic Response (CCyR) at 12 Cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival (PFS-1L)
Endpoint domain: Mortality/survival
Primary endpoint: Revision for any reason
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes from baseline levels of regular exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline cardiovascular endurance/aerobic fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life measured as a Short Form Health Survey - 36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life measured as a Moorehead-Ardelt Quality of Life Questionnaire II score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Correlation Coefficient Between HEP and OVF Mean Deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: loss to contact after suicide attempt
Endpoint domain: Adverse events/effects
Primary endpoint: Change in diffusivity indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gray matter changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quantification of white matter lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VH 0 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doppler ultrasound results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart muscle scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of solicited injection site and systemic reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of study vaccine-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects achieving a serum HAI antibody titer of 1:40 or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of clinical safety laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximally Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence or presence of live head lice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in liver fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores on standardized tests of processing speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum tolerable dose of Nintedanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AAA related mortality
Endpoint domain: Mortality/survival
Primary endpoint: AAA related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Index (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of mucosal breaks in the small bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Metabolic Equivalents (METS) at Six Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in Anxiety and Depression Scores (Hospital Anxiety and Depression Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bayley scales of infant development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects receiving influenza vaccine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in pain associated with trigeminal neuralgia (BPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain associated with trigeminal neuralgia (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24hr excretion of bioactive compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke within 30 days after the procedure
Endpoint domain: Mortality/survival
Primary endpoint: Myoma symptom control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful Defibrillation Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Migraine-Specific Quality of Life (MSQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complication rate of patients with bleeding requiring re-operation
Endpoint domain: Adverse events/effects
Primary endpoint: Complication rate of patients with infection requiring antibiotics or re-operation
Endpoint domain: Adverse events/effects
Primary endpoint: Discharge location
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants Achieving >= 50% Reduction in Simple Endoscopic Score for Crohn's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative haemodynamic instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Outcome Questionnaire-45
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IV morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Worsening of Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mass balance of BCX4161
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient's metabolic state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: the patient's weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient's quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Euploid embryo rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes